Please login to the form below

Not currently logged in
Email:
Password:

Chiesi Group

This page shows the latest Chiesi Group news and features for those working in and with pharma, biotech and healthcare.

Chiesi's ultra-rare genetic disorder therapy wins European backing

Chiesi's ultra-rare genetic disorder therapy wins European backing

Chiesi Group’s Lamzede (velmanase alfa) has been recommended for approval in Europe, putting it on course to become the first pharmacological therapy to reach the market for Alpha-Mannosidosis (AM). ... Paolo Chiesi, vice president and head of R&D for

Latest news

  • Chiesi Group's Trimbow wins European licence Chiesi Group's Trimbow wins European licence

    Chiesi Group's Trimbow wins European licence. European Commission approves the COPD treatment. ... The European Commission has approved Chiesi Group’s Trimbow to treat adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are

  • Communiqué Awards 2007: Results

    Finalists:. Agency:iS. Client:Pfizer. Campaign:Welcome to CALM. Agency:Say Communications/ EuroPR Group. Client:Nutricia. ... Client:Schering Health Care. Campaign:Living with MS. Agency:Medicom Group. Client:Trinity-Chiesi Pharmaceuticals.

  • Communiqué Awards 2008: Results

    Agency:Medicom Group. Client:Trinity-Chiesi. Campaign:Clenil Modulite Medical Education Programm. ... Agency:Medicom Group. Client:Smith &Nephew. Campaign: 'Touch' Magazine. GO TO: Campaign Awards:.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics